The capacity to colonize the small intestine seems to be an important prerequisite for enterotoxin-producing Escherichia coli (ETEC) to cause diarrhea. On ETEC strains isolated from humans, several distinct types of putative adherence fimbriae that are immunologically nonrelated have been identified. The best recognized of these fimbriae are the colonization factor antigens (CFAs) I and II (CFA/I and CFA/II) and CFA/IV (formerly designated PCF8775) (7, 9, 11, 26, 27, 29) , but additional ones have been described previously (4, 15) . The expression of CFAs is controlled by plasmids which, in most cases, also encode for the production of a heat-stable enterotoxin (23) and, in some instances, also for a heat-labile enterotoxin of E. coli (28) .
CFA/I is expressed as threadlike appendages that are located on the surface of ETEC. In the electron microscope these fimbriae are seen as rather rigid structures of 0.5 to 1 ,um in length with a diameter of 7 nm (20, 21) . The fimbriae consist of more than 100 identical subunits of CFA/I that are made up of 147 amino acid residues; each subunit has a molecular weight of 15,058 (13) .
The ability of ETEC to cause hemagglutination of human blood group A erythrocytes in the presence of D-mannose has been used to screen for the presence of CFA/I. In a recent report (1) , we have shown that slide agglutination with polyclonal antisera against purified CFA/I is a very sensitive and specific method for the identification of CFA/I on ETEC isolates.
Studies in humans have shown that CFA/I is important for the capacity of ETEC to colonize the intestine and to produce diarrhea (11) . Antibodies against CFA/I are also important in preventing colonization and disease by CFA/Ipositive strains in experimental animals (2, 6) , and immunization with purified CFA/I has been reported to induce protective immunity in humans (10) . Against this background it is most likely that CFA/I fimbriae, the subunit protein, or perhaps synthetic peptides harboring major anti-genic determinants on CFA/I should be included in a future ETEC vaccine.
The aim of this study was to raise monoclonal antibodies (MAbs) against CFA/I for use in the identification of CFA/Tpositive bacteria. Another aim was to analyze whether the MAbs produced were directed against the same or different epitopes on the CFA/I subunit protein. The results suggest that most but not all of the MAbs are directed against epitopes that are located on the surface of native fimbriae.
MATERIALS AND METHODS
Bacteria. The CFA/I-carrying ETEC strain H10407 (078: K80:H11; CFA/I), which was kindly obtained from Dolores Evans (Houston, Tex.) and 15 previously CFA/I-positive strains isolated from patients with diarrhea during an epidemiological study in Dhaka, Bangladesh (12), were used. In addition, eight CFA/II-positive strains isolated in Dhaka (12) and two CFA/IV-positive strains kindly provided by B. Rowe (Colindale, London, England) were used for specificity analysis.
Antigens. Purified CFA/I was prepared from a flagellumdeficient mutant of strain H10407 (kindly provided by Dolores Evans) as described previously (8) . The CFA/I preparation was checked for purity by double diffusion in gel (22) by using a polyclonal serum against strain H10407 or by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (16) . CFA/Il was similarly purified from a CFA/JT-positive strain, E1392-75 (06:H16), expressing E. coli surface antigens CS1 and CS3 and from a CFA/II-positive strain expressing CS2 and CS3 (3, 24) .
CFA/IV antigen was purified by the same methodology described above from strain C916/82, which expresses CS4 and CS6; however, this purification only resulted in the isolation of purified CS4, whereas the nonfimbrial CS6 antigen was lacking in the fimbrial preparation. (5) . After 10 to 14 days (mean, 12 days) the hybridomas were tested for the production of antibodies against CFA/I in an enzyme-linked immunosorbent assay (ELISA), and the hybrids producing the highest titers were cloned and expanded by cultivation in 10 ml of fetal bovine serum-Iscove medium. Two of the hybridomas were selected for further growth, including preparation of ascites fluid as described previously (19) . All cell lines were frozen in the presence of dimethyl sulfoxide and 10% fetal bovine serum in liquid nitrogen.
ELISA. MAbs against CFA/I were identified by a CFA/I ELISA method. ELISA microtiter plates (Nunc, A/S Roskilde, Denmark) were coated with a 5 ,ug of purified CFA/I per ml at 37°C overnight (100 ,ul per well). After the plates were blocked with a 1% bovine serum albumin (BSA)-phosphate-buffered saline (PBS) solution at 37°C for 30 min, supernatants from hybridomas (culture fluids) diluted 1:2 in PBS containing 0.1% BSA (100 ,ul per well) were incubated in the plates at room temperature for 2 h. Bound antibody was then demonstrated by the addition of anti-mouse immunoglobulin-horseradish peroxidase conjugate and orthophenylenediamine-H202 enzyme substrate, as described previously (25) . Culture fluids giving an A450 of .0.2 above the background at 20 min were considered to be positive for CFA/I.
The capacity of purified CFA/I, peptide fragments of the CFA/I subunit protein, and CFA-carrying E. coli to inhibit binding of the anti-CFA/I MAbs to solid-phase-bound CFA/I was assayed by an ELISA inhibition method. All the different MAbs were diluted in 0.1% BSA-PBS to a concentration corresponding to 10 times the ELISA titer against purified CFA/I. The diluted MAbs were then mixed with equal volumes of twofold dilutions of purified CFA/I (1 mg/ ml), peptide fractions (0.5 to 3 mg/ml), or whole bacteria (1010 bacteria per ml). After the mixtures were added to the CFA/I-coated plates and incubated at room temperature for 2 h, the plates were developed as described above for the CFA ELISA. The concentration of inhibitor that resulted in 50% inhibition of binding of the respective MAbs to solidphase-bound CFA/I was determined.
The capacity of different anti-CFA/I MAbs to inhibit binding of heterologous anti-CFA/I MAbs to solid-phasebound CFA/I was also studied by ELISA. Several dilutions of anti-CFA/I MAb were incubated in a CFA/I-coated ELISA microtiter plate at room temperature for 2 h. After washing 3 times in PBS, the homologous or heterologous anti-CFA/I MAb coupled to alkaline phosphatase (AP) (17) was added; the concentration of the different anti-CFA/I-AP conjugates to be used was determined by checkerboard titrations. After incubation of the AP-coupled MAbs at room temperature for 2 h, the plates were developed with enzyme substrate (nitrophenylphosphate, 1 mg/ml, in ethanolamine buffer [pH 9.6] ).
Slide agglutination tests. Bacteria (10 ,ul; about 1010 organisms per ml) were mixed with 10 ,ul of either nondiluted or 3-to 5-fold-concentrated culture fluid of MAb or with 1:10-fold-diluted ascites fluid of the different anti-CFA/I MAbs on a glass slide. Macroscopically visible agglutinates observed within 2 min were regarded as a positive reaction.
Hemagglutination inhibition was performed by mixing 10 ,ul of a suspension of CFA/I-positive bacteria with 10 ,ul of diluted MAbs on a glass slide for 1 min and then adding 10 20 ptg of CFA/I per ml. After electrophoresis was carried out as described previously (25) , the separated samples were transferred to a nitrocellulose sheet for 4 h at 180 mA. The nitrocellulose sheet was then incubated in a 1% BSA-PBS solution for 1 h, followed by washing 3 times in PBS and incubation with anti-CFA MAb diluted in a 0.1% BSA-PBSTween solution for 16 h at room temperature. The nitrocellulose sheets were developed with enzyme conjugate and substrate as described previously (17, 25) .
Nitrocellulose replica method. In some experiments CFA/Ipositive and CFA-negative E. coli were cultured onto CFA agar, and replicas of the cultures on nitrocellulose filter papers were performed as described previously (17) . After the paper was blocked with 1% BSA-PBS, ascites fluid of anti-CFA/I MAbs diluted in 0.1% BSA-PBS was added for 1 h, and the paper was developed with anti-mouse immunoglobulin-horseradish peroxidase conjugate and enzyme substrate as described previously (17) .
Proteolytic and chemical cleavage of CFA/I fimbriae. Digestion of purified CFA/I fimbriae with trypsin and subsequent isolation of soluble peptides with different amino acid lengths, as well as cleavage with cyanogen bromide, was performed as described previously (14) .
RESULTS
Frequency and isotype of anti-CFA/I MAbs. Culture fluids from all stable hybrids from the different cell fusion experiments were studied for production of anti-CFA/I antibody by ELISA. Altogether, 25 shown). When CFA/I-carrying bacteria and the corresponding CFA-negative mutants adsorbed onto separated nitrocellulose replicas were reacted with these anti-CFA/I MAbs and the filter papers were developed by ELISA (17), a positive reaction was only obtained for replicas that were treated with CFA/I-fimbriated bacteria (Fig. 1) .
To evaluate further the specificity of the different MAbs for CFA/I, they were tested for inhibition of binding to solid-phase-bound CFA/I by various purified CFAs and CFA-carrying bacteria. Although all of the 17 MAbs tested were adjusted to the same antibody concentration, i.e., 10 times the ELISA titer against CFA/I, slightly varied concentrations of purified CFA/I (1 to 6 Fi.g/ml) were needed to obtain 50% inhibition of their binding to solid-phase antigen. This difference in inhibitory capacity of CFA/I suggests slightly different avidities of the MAbs for the specific antigen. In no instance were any of the anti-CFA/I MAbs inhibited by 1 mg of purified CFA/II (CS1 and CS3 or CS2 and CS3) per ml or by the purified CS4 component of CFA/ IV. When CFA/I-positive bacteria were tested, it was found that all but one of the MAbs tested were inhibited by such organisms but that none of the MAbs was inhibited by bacteria expressing CFA/Il or CFA/IV or by CFA/I-deficient mutants (strains H10407P and 258909-3M).
Inhibition ELISA. The ability of different anti-CFA/T MAbs to inhibit one of the anti-CFA/I MAbs, 1:6, coupled to AP was tested by ELISA. This was done by incubating one dilution of the different MAbs, corresponding to 10 times the ELISA titer against CFA/I, in CFA-coated plates for 1 h and then adding the MAb 1:6-AP conjugate to the plates. It was found that eight of the 24 anti-CFA/I MAbs tested did not inhibit binding of the MAb 1:6-AP conjugate at all; four MAbs gave only partial inhibition (-50%), whereas 12 MAbs inhibited binding of MAb 1:6 by 100% (Fig. 2) . The poor inhibitory capacity of some of the MAbs, even though they were used at high concentrations (10 to 30 ,ug/ml), suggests that they bound with a comparatively low avidity to purified CFA/I or that they recognized a different antigenic determinant than MAb 1:6.
Agglutinating ability of anti-CFA/I MAbs. Twenty of the MAbs were examined for their ability to agglutinate E. coli strains that were previously shown to express CFA/t, CFA/II, or CFA/IV antigen. Culture fluids of the MAbs concentrated one-to fivefold or ascites fluid diluted 1/10 were used in these analyses. Most CFA/I-positive strains (n = 16) Comparison of agglutinating and nonagglutinating MAbs. For further analyses, two IgGl MAbs that both reacted in high, almost similar, titers with CFA/I in the ELISA (MAb 1:6, which agglutinated all the 20 CFA/I-positive strains, and MAb 65D, which did not agglutinate any of these strains) were compared in different assays for their reactivities with CFA/I. The capacities of E. coli expressing CFA/I to inhibit binding of diluted MAbs 1:6 and 65D to solid-phase-bound CFA/I were compared. Whereas purified CFA/I was very efficient to inhibit the bindifig of the two MAbs to the solid phase, only MAb 1:6 was inhibited by CFA/I-carrying bacteria (Fig. 3) . The hemagglutination-inhibitory capacity of the two MAbs was also tested. It was found that whereas the culture medium of MAb 1:6 effectively inhibited hemagglutination of human blood group A erythrocytes by CFA/Icarrying bacteria at a dilution of 1/100, even concentrated medium of MAb 65D had no such inhibitory effect.
In a further attempt to evaluate whether MAbs 65D and 1:6 were directed against different epitopes on CFA/I, we performed cross-inhibition experiments with these MAbs by ELISA. After incubation of different dilutions of the respective MAbs in CFA/I-coated ELISA plates, MAb 1:6 or 65D covalently coupled to AP was added and assayed for binding to the solid phase. It was found that although the two MAb preparations contained equal concentrations of specific IgGl antibodies, only MAb 1:6 effectively inhibited subsequent binding of either of the two enzyme-conjugated MAb preparations. Thus, ascites fluid of MAb 1:6 diluted 1/10,000 inhibited subsequent binding of both MAb 1:6-AP and MAb 65D-AP by 50%. Initial incubation with ascites fluid of MAb 65D gave only partial inhibition (50 to 60%) of subsequent binding of the homologous and heterologous MAb-AP con- Fig. 4 ) to inhibit binding of the two MAbs to solid-phase-bound CFA/I. We found that the only one of the six fragments tested that effectively inhibited binding of either MAb was a peptide corresponding to the N-terminal 46 amino acid residues of the CFA/I protein; the inhibition of MAb 65D was considerably better than that of MAb 1:6 (Table 2) . A number of shorter peptides covering various parts of the N-terminal 46 amino acid residues (Fig. 4) (15) at concentrations of up to 200 nmol/ml failed to inhibit the binding of either of the MAbs to solid-phase CFA/I (compared with purified CFA/I, which inhibited the binding by 50% at concentrations of 0.03 to 0.07 nmol/ml). Attempts to determine the direct binding of the anti-CFA/I MAbs to the different peptides failed since none of the MAbs bound significantly to ELISA plates coated with a wide range of concentrations (0.1 to 100 ,ug/ml) of the different peptides presented in Fig. 4 .
DISCUSSION
We produced and characterized a number of MAbs which bind to CFA/I-fimbriated bacteria as well as to isolated CFA/I fimbriae. As many as 65% of these MAbs agglutinated all 16 CFA/I-positive E. coli strains tested, whereas none of the MAbs agglutinated CFA/I-deficient mutants or CFA/IIand CFA/IV-positive bacteria. Against this background several of these anti-CFA/I-specific MAbs may be used as immunodiagnostic reagents in the identification of CFA/Ipositive ETEC, e.g., in epidemiological studies. We also identified a MAb, 65D, that did not recognize native CFA/I fimbriae when they were present on bacteria, but it was able to react with isolated and dissociated CFA/I subunits, sug- VEKtilTMIMT-E --VIEAAPAAVISUMEVIAGTG (17) , is that they can be used specifically to detect CFA-carrying E. coli excreted in the stools of people without prior isolation of ETEC.
Worobec et al. (30) have previously reported the production of MAbs against CFA/I. The four MAbs they studied by electron microscopy appeared to bind with a similar pattern along the surface of the entire CFA/I pilus, suggesting that they were all directed against the same epitope that was accessible on whole fimbriae. On the other hand, only one of the four MAbs cross-reacted with K99 antigen, suggesting that it has a specificity for at least partially different epitopes.
The fact that MAb 65D recognized isolated fimbriae as well as the 15-kilodalton subunit, but failed to agglutinate whole bacteria carrying CFA/I, suggests that it recognizes an epitope which is partially or completely masked on native fimbriae but that is exposed on denatured or depolymerized CFA/I protein. This is further supported by our finding that isolated CFA/I fimbriae, but not E. coli expressing comparatively high levels of CFA/I fimbriae, inhibited the binding of MAb 65D to solid-phase-bound CFA/I. The failure of MAb 65D, at variance with MAb 1:6, to inhibit hemagglutination of human erythrocytes by CFA/I-carrying bacteria strongly supports the fact that MAb 65D is not directed against an epitope that is expressed on the receptor-binding portion of native CFA/I.
Based on the elucidated amino acid sequence of the CFA/I subunit protein (13) , six potential antigenic determinants have previously been predicted (14) . Two of these potential determinants are located within the N-terminal 46 amino acid residues. The two different MAbs, 1:6 and 65D, which are agglutinating and nonagglutinating, respectively, were inhibited by a peptide that encompasses this region of the protein. This finding may suggest that the two MAbs are directed against two different, but proximate, epitopes within the first 46 amino acid residues. Alternatively, only the epitope to which MAb 65D binds specifically is restricted to this region. Thus, whereas the 46-amino-acid fragment was almost as effective as purified CFA/I in inhibiting the binding of MAb 65D to solid-phase-bound CFA/I, this fragment was, on a molar basis, at least 15-fold less effective than the CFA/I protein in inhibiting the binding of MAb 1:6. This might suggest that the MAb 1:6 epitope is only partially located within the N-terminal 46 amino acid residues or that it is dependent on the tertiary configuration of the CFA/I subunit protein.
It is somewhat suprising that a peptide corresponding to the N-terminal 78 amino acid residues only has a marginal inhibitory effect on MAb 65D (Table 2) , and we must assume that this peptide folds up in a conformation in which the epitope in question is either shielded or in the wrong configuration. 
